Stocks · News reference
Enliven’s Lead Drug Could Disrupt The Leukemia Treatment Market, Analyst Says
William Blair initiates Enliven Therapeutics (ELVN) with Outperform, highlighting ELVN-001's strong CML trial data & $8.8B market potential.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Novartis Reports Tumor Cases Linked to Zolgensma Gene Therapy
Novartis has identified nine reports of tumors in patients treated with its gene therapy Zolgensma since its 2019 approval, with two cases showing evidence of a link to the treatment.
Schrödinger Amends Collaboration Agreement with Novartis
Schrödinger has amended its existing collaboration with Novartis, replacing previous programs with two new ones and increasing potential milestone payments to $1.424 billion.
Novartis Venture Fund Participates in €40 Million Series A Financing for Anaheim Bio
Novartis Venture Fund joined a group of investors in a €40 million Series A financing round for the newly launched Dutch biotechnology company Anaheim Bio.
Monte Rosa Therapeutics Announces Third Quarter 2026 Financial Results and Business Updates
Monte Rosa Therapeutics announced positive Phase 1 results for MRT-8102, showing significant NEK7 degradation and reduction in cardiovascular disease markers with safety comparable to placebo. The company plans to initiate three Phase 2 studies in gout, coronary artery disease, and hidradenitis suppurativa. Additionally, Novartis initiated Phase 2 studies of partnered program MRT-6160 in Sjögren's disease and psoriatic arthritis, triggering $87.5 million in milestone payments. The company maintains a strong cash position of $582.6 million, expected to support operations into 2029.
Novartis Italia Presents Catalyst Project
Novartis Italia introduced its Catalyst project during the 'Innovazione che cambia la vita' event, highlighting new initiatives in the local market.